Colección SciELO Chile

Departamento Gestión de Conocimiento, Monitoreo y Prospección
Consultas o comentarios: productividad@anid.cl
Búsqueda Publicación
Búsqueda por Tema Título, Abstract y Keywords



ANNALS OF ONCOLOGY
ISSN 0923-7534
E-ISSN 1569-8041
País S/I
Indexación WoS Scopus

Publicaciones Chile en el período 2008-2021

Autores Chile en el período 2008-2021


Factor de Impacto WoS




Año Factor de Impacto
2011 6.425
2012 7.384
2013 7.384
2014 7.04
2015 9.269
2016 11.855
2017 13.926
2018 14.196
2019 18.274
2020 18.274
2021 18.274

Muestra el factor de impacto de la revista seleccionada en el tiempo.

Disciplinas y Ranking




Año Ranking Cuartil

Muestra la distribución de disciplinas para la revista.

Cuartiles desplegados de acuerdo a WoS, consultando el Journal Citation Report. Estos cuartiles pueden variar dependiendo de la disciplina consultada.

Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.

Origen de las citas recibidas por la revista



Nombre Revista ISSN/ISBN Indexacion Citas
Annals of Intensive Care 2110-5820 WOS, Scopus 3
ecancermedicalscience 1754-6605 WOS, Scopus 1
CLINICAL CANCER RESEARCH 1078-0432 WOS, Scopus 15
EUROPEAN JOURNAL OF CANCER 0959-8049 WOS, Scopus 18
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 0360-3016 WOS, Scopus 1
CANCER TREATMENT REVIEWS 0305-7372 WOS, Scopus 12
RADIOTHERAPY AND ONCOLOGY 0167-8140 WOS, Scopus 2
LANCET 0140-6736 WOS, Scopus 2
SCIENTOMETRICS 0138-9130 WOS, Scopus 1
CLINICS 1807-5932 Externa 1
DRUGS & AGING 1170-229X Externa 2
FRONTIERS IN PHARMACOLOGY 1663-9812 Externa 4
MEDICINE 0025-7974 Externa 5
CRITICAL CARE MEDICINE 0090-3493 Externa 2
PLOS ONE 1932-6203 Externa 17
PHARMACOLOGY & THERAPEUTICS 0163-7258 Externa 2
DRUGS 0012-6667 Externa 6
WORLD JOURNAL OF GASTROENTEROLOGY 1007-9327 Externa 18
BREAST 0960-9776 Externa 4
BIOMED RESEARCH INTERNATIONAL 2314-6133 Externa 7
HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL 1499-3872 Externa 1
CHEMICAL SOCIETY REVIEWS 0306-0012 Externa 1
CHIRURG 0009-4722 Externa 2
JOURNAL OF GASTROINTESTINAL SURGERY 1091-255X Externa 3
NEW ENGLAND JOURNAL OF MEDICINE 0028-4793 Externa 4
BIOBANKING IN THE 21ST CENTURY 0065-2598 Externa 3
HEALTH TECHNOLOGY ASSESSMENT 1366-5278 Externa 1
EXPERT OPINION ON PHARMACOTHERAPY 1465-6566 Externa 3
VALUE IN HEALTH 1098-3015 Externa 1
NONEQUILIBRIUM STATISTICAL MECHANICS AND NONLINEAR PHYSICS 0094-243X Externa 1
SCIENTIFIC REPORTS 2045-2322 Externa 11
BIOMEDICINE & PHARMACOTHERAPY 0753-3322 Externa 2
FRONTIERS IN PHYSIOLOGY 1664-042X Externa 1
ARCHIVES OF BIOLOGICAL SCIENCES 0354-4664 Externa 1
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 0815-9319 Externa 3
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS 1473-7159 Externa 1
JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION 0030-9982 Externa 1
EUROPEAN RESPIRATORY JOURNAL 0903-1936 Externa 2
ANALYTICAL CHEMISTRY 0003-2700 Externa 1
ONCOGENE 0950-9232 Externa 3
ACTA CHIRURGICA BELGICA 0001-5458 Externa 2
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION 1513-7368 Externa 2
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS 0973-1482 Externa 1
SURGERY 0039-6060 Externa 6
ANNALS OF SURGERY 0003-4932 Externa 3
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 0223-5234 Externa 1
PATHOLOGY INTERNATIONAL 1320-5463 Externa 1
NATURE 0028-0836 Externa 1
CLINICAL NUCLEAR MEDICINE 0363-9762 Externa 1
CHEST 0012-3692 Externa 1
UROLOGE-AUSGABE A 0340-2592 Externa 1
JOURNAL OF CLINICAL PATHOLOGY 0021-9746 Externa 1
HISTOPATHOLOGY 0309-0167 Externa 5
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 0006-291X Externa 1
NATIONAL MEDICAL JOURNAL OF INDIA 0970-258X Externa 1
COCHRANE DATABASE OF SYSTEMATIC REVIEWS 1469-493X Externa 1
MOLECULES 1420-3049 Externa 1
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 1542-3565 Externa 1
AMERICAN JOURNAL OF SURGICAL PATHOLOGY 0147-5185 Externa 5
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH 0300-0605 Externa 1
ANNALS OF ONCOLOGY 0923-7534 Externa 32
JOURNAL OF SURGICAL ONCOLOGY 0022-4790 Externa 9
VIRCHOWS ARCHIV 0945-6317 Externa 7
JOURNAL OF SURGICAL RESEARCH 0022-4804 Externa 2
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 0031-6970 Externa 1
INTERNATIONAL JOURNAL OF ONCOLOGY 1019-6439 Externa 2
ZEITSCHRIFT FUR GASTROENTEROLOGIE 0044-2771 Externa 1
BREAST CANCER RESEARCH AND TREATMENT 0167-6806 Externa 1
CANCER 0008-543X Externa 10
INTERNATIONAL JOURNAL OF CANCER 0020-7136 Externa 10
NATURE REVIEWS CANCER 1474-175X Externa 3
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE 1940-5901 Externa 3
DISEASES OF THE COLON & RECTUM 0012-3706 Externa 11
REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS 1130-0108 Externa 1
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA 0889-8588 Externa 1
EJSO 0748-7983 Externa 18
TUMOR BIOLOGY 1010-4283 Externa 2
CHINESE CLINICAL ONCOLOGY 2304-3865 Externa 1
LANCET ONCOLOGY 1470-2045 Externa 18
REVUE DES MALADIES RESPIRATOIRES 0761-8425 Externa 4
HUMAN PATHOLOGY 0046-8177 Externa 2
INTERNATIONAL JOURNAL OF UROLOGY 0919-8172 Externa 1
SWISS MEDICAL WEEKLY 1424-7860 Externa 1
IN VIVO 0258-851X Externa 4
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE 1368-5031 Externa 1
BRITISH JOURNAL OF SURGERY 0007-1323 Externa 3
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE 0179-1958 Externa 19
CURRENT ONCOLOGY 1198-0052 Externa 6
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 0012-0472 Externa 1
CHINESE MEDICAL JOURNAL 0366-6999 Externa 1
BMJ OPEN 2044-6055 Externa 3
CURRENT DRUG TARGETS 1389-4501 Externa 1
INTENSIVE CARE MEDICINE 0342-4642 Externa 4
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY 2210-7401 Externa 3
GASTROINTESTINAL ENDOSCOPY 0016-5107 Externa 1
JOURNAL OF NEUROLOGY 0340-5354 Externa 1
CANCER RESEARCH 0008-5472 Externa 1
JOURNAL OF GASTROENTEROLOGY 0944-1174 Externa 1
DIGESTIVE AND LIVER DISEASE 1590-8658 Externa 2
INTERNATIONAL JOURNAL OF POLYMERIC MATERIALS 0091-4037 Externa 1
ADVANCES IN THERAPY 0741-238X Externa 2
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS 0277-3732 Externa 1
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE 0003-9985 Externa 1
GUT 0017-5749 Externa 2
BRAIN PATHOLOGY 1015-6305 Externa 1
ANZ JOURNAL OF SURGERY 1445-1433 Externa 1
EUROPEAN UROLOGY 0302-2838 Externa 2
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY 1521-6918 Externa 1
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 1422-0067 Externa 5
ONCOLOGIST 1083-7159 Externa 5
PATHOLOGY RESEARCH AND PRACTICE 0344-0338 Externa 3
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES 1128-3602 Externa 1
SURGERY TODAY 0941-1291 Externa 6
FASEB JOURNAL 0892-6638 Externa 1
DIGESTION 0012-2823 Externa 1
MODERN PATHOLOGY 0893-3952 Externa 2
REVISTA DA ASSOCIACAO MEDICA BRASILEIRA 1806-9282 Externa 1
JOURNAL OF CRITICAL CARE 0883-9441 Externa 1
CLINICAL THERAPEUTICS 0149-2918 Externa 1
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY 1010-7940 Externa 1
ZENTRALBLATT FUR CHIRURGIE 0044-409X Externa 1
CLINICAL RADIOLOGY 0009-9260 Externa 2
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 1040-8428 Externa 7
HISTOLOGY AND HISTOPATHOLOGY 0213-3911 Externa 1
CLINICAL RESPIRATORY JOURNAL 1752-6981 Externa 1
PATHOLOGY & ONCOLOGY RESEARCH 1219-4956 Externa 1
INTERNATIONAL SURGERY 0020-8868 Externa 1
CA-A CANCER JOURNAL FOR CLINICIANS 0007-9235 Externa 1
DIGESTIVE SURGERY 0253-4886 Externa 1
JOURNAL OF GASTROINTESTINAL CANCER 1941-6628 Externa 2
CIRUGIA ESPANOLA 0009-739X Externa 2
JOURNAL OF THE NATIONAL CANCER INSTITUTE 0027-8874 Externa 1
WEST INDIAN MEDICAL JOURNAL 0043-3144 Externa 1
AMERICAN JOURNAL OF SURGERY 0002-9610 Externa 2
ADVANCES IN CANCER RESEARCH 0065-230X Externa 1
GEBURTSHILFE UND FRAUENHEILKUNDE 0016-5751 Externa 2
NEOPLASIA 1476-5586 Externa 1
JOURNAL OF CLINICAL PHARMACOLOGY 0091-2700 Externa 1
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS 0739-1102 Externa 1
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY 1942-0900 Externa 1
ONCOTARGETS AND THERAPY 1178-6930 Externa 7
THERANOSTICS 1838-7640 Externa 1
LANCET GASTROENTEROLOGY & HEPATOLOGY 2468-1253 Externa 1
INTERNIST 0020-9554 Externa 1
WORLD JOURNAL OF UROLOGY 0724-4983 Externa 1
JOURNAL OF CLINICAL MEDICINE 2077-0383 Externa 5
ANNALS OF SURGICAL ONCOLOGY 1068-9265 Externa 15
UPDATES IN SURGERY 2038-131X Externa 2
LANGENBECKS ARCHIVES OF SURGERY 1435-2443 Externa 4
FRONTIERS IN MEDICINE 2296-858X Externa 1
VISCERAL MEDICINE 2297-4725 Externa 1
NATURE COMMUNICATIONS 2041-1723 Externa 3
MOLECULAR DIAGNOSIS & THERAPY 1177-1062 Externa 1
MEDICINA-LITHUANIA 1010-660X Externa 1
LANCET RESPIRATORY MEDICINE 2213-2600 Externa 4
MEDICINA INTENSIVA 0210-5691 Externa 2
JCI INSIGHT 2379-3708 Externa 1
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY 1936-2625 Externa 1
PHARMACEUTICALS 1424-8247 Externa 2
FRONTIERS IN IMMUNOLOGY 1664-3224 Externa 3
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH 1473-7167 Externa 1
EXPERT OPINION ON BIOLOGICAL THERAPY 1471-2598 Externa 6
BMC PULMONARY MEDICINE 1471-2466 Externa 1
EUROPEAN RADIOLOGY 0938-7994 Externa 3
CANCERS 2072-6694 Externa 17
BMC CANCER 1471-2407 Externa 30
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS 1072-7515 Externa 1
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY 1341-9625 Externa 6
ANNALS OF TRANSLATIONAL MEDICINE 2305-5839 Externa 6
CANCER LETTERS 0304-3835 Externa 6
FRONTIERS IN ENDOCRINOLOGY 1664-2392 Externa 1
JOURNAL OF CLINICAL ONCOLOGY 0732-183X Externa 14
CANCER MANAGEMENT AND RESEARCH 1179-1322 Externa 4
JOURNAL FOR IMMUNOTHERAPY OF CANCER 2051-1426 Externa 5
CANCER IMMUNOLOGY IMMUNOTHERAPY 0340-7004 Externa 3
ACTA CLINICA BELGICA 1784-3286 Externa 1
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY 1865-5041 Externa 1
FRONTIERS IN ONCOLOGY 2234-943X Externa 11
CUREUS 2168-8184 Externa 2
ENDOSCOPY 0013-726X Externa 1
BIOENGINEERED 2165-5979 Externa 1
CANCER COMMUNICATIONS 2523-3548 Externa 2
MOLECULAR MEDICINE REPORTS 1791-2997 Externa 1
EXPERT OPINION ON THERAPEUTIC TARGETS 1472-8222 Externa 1
WORLD JOURNAL OF CLINICAL CASES 2307-8960 Externa 2
UPSALA JOURNAL OF MEDICAL SCIENCES 0300-9734 Externa 1
BIOSCIENCE TRENDS 1881-7815 Externa 1
STEM CELLS INTERNATIONAL 1687-966X Externa 1
RESPIRATORY MEDICINE CASE REPORTS 2213-0071 Externa 1
JOURNAL OF CANCER 1837-9664 Externa 6
CRITICAL CARE 1466-609X Externa 1
CELL DEATH & DISEASE 2041-4889 Externa 2
TRANSLATIONAL LUNG CANCER RESEARCH 2218-6751 Externa 1
LUNG CANCER 0169-5002 Externa 7
TRANSLATIONAL CANCER RESEARCH 2218-676X Externa 5
LAEKNABLADID 0023-7213 Externa 1
CURRENT ONCOLOGY REPORTS 1523-3790 Externa 3
JOURNAL OF THORACIC DISEASE 2072-1439 Externa 7
NATURE REVIEWS CLINICAL ONCOLOGY 1759-4774 Externa 8
BREAST JOURNAL 1075-122X Externa 1
EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT 2380-8993 Externa 4
BREAST CARE 1661-3791 Externa 1
TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY 2415-1289 Externa 5
FUTURE ONCOLOGY 1479-6694 Externa 11
ONCOIMMUNOLOGY 2162-402X Externa 8
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH 1756-9966 Externa 1
THORACIC CANCER 1759-7706 Externa 2
EXPERIMENTAL HEMATOLOGY & ONCOLOGY 2162-3619 Externa 2
JOURNAL OF GERIATRIC ONCOLOGY 1879-4068 Externa 4
CANCER DISCOVERY 2159-8274 Externa 4
TARGETED ONCOLOGY 1776-2596 Externa 6
UROLOGY 0090-4295 Externa 1
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK 1540-1405 Externa 2
ANTIBODIES 2073-4468 Externa 1
BIOMEDICINES 2227-9059 Externa 1
JAPANESE JOURNAL OF CLINICAL ONCOLOGY 0368-2811 Externa 2
CLINICAL & TRANSLATIONAL ONCOLOGY 1699-048X Externa 8
BULLETIN DU CANCER 0007-4551 Externa 3
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY 1758-8340 Externa 8
ACTA ONCOLOGICA 0284-186X Externa 18
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY 1543-0790 Externa 2
EXPERT REVIEW OF ANTICANCER THERAPY 1473-7140 Externa 4
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 0171-5216 Externa 6
VACCINES 2076-393X Externa 1
ANTICANCER RESEARCH 0250-7005 Externa 21
GASTRIC CANCER 1436-3291 Externa 7
JOURNAL OF THE CHINESE MEDICAL ASSOCIATION 1726-4901 Externa 1
TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY 2224-476X Externa 1
JOURNAL OF HEMATOLOGY & ONCOLOGY 1756-8722 Externa 2
FRONTIERS OF MEDICINE 2095-0217 Externa 1
EPIGENOMICS 1750-1911 Externa 1
ONCOLOGY RESEARCH AND TREATMENT 2296-5270 Externa 4
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS 1528-4042 Externa 1
BIOESSAYS 0265-9247 Externa 1
DECISION SUPPORT SYSTEMS 0167-9236 Externa 1
EXPERT REVIEW OF RESPIRATORY MEDICINE 1747-6348 Externa 1
RADIOLOGE 0033-832X Externa 1
JOURNAL OF LAPAROENDOSCOPIC & ADVANCED SURGICAL TECHNIQUES 1092-6429 Externa 3
ABCD-ARQUIVOS BRASILEIROS DE CIRURGIA DIGESTIVA-BRAZILIAN ARCHIVES OF DIGESTIVE SURGERY 0102-6720 Externa 1
LYMPHATIC RESEARCH AND BIOLOGY 1539-6851 Externa 1
MOLECULAR THERAPY-NUCLEIC ACIDS 2162-2531 Externa 1
AMERICAN JOURNAL OF ROENTGENOLOGY 0361-803X Externa 1
SIGNAL TRANSDUCTION AND TARGETED THERAPY 2095-9907 Externa 1
MOLECULAR CANCER 1476-4598 Externa 2
IMMUNOTHERAPY 1750-743X Externa 7
CHINESE MEDICINE 1749-8546 Externa 1
MOLECULAR ONCOLOGY 1574-7891 Externa 1
RADIOLOGY AND ONCOLOGY 1318-2099 Externa 2
JAMA INTERNAL MEDICINE 2168-6106 Externa 1
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH 1943-8141 Externa 1
BRITISH JOURNAL OF CANCER 0007-0920 Externa 20
ESMO OPEN 2059-7029 Externa 7
JOURNAL OF KOREAN MEDICAL SCIENCE 1011-8934 Externa 1
EMBO MOLECULAR MEDICINE 1757-4676 Externa 1
TERRITORY POLITICS GOVERNANCE 2162-2671 Externa 1
JOURNAL OF MEDICAL ECONOMICS 1369-6998 Externa 1
JAMA NETWORK OPEN 2574-3805 Externa 1
GASTROENTEROLOGE 1861-9681 Externa 4
BIOTECHNOLOGY ADVANCES 0734-9750 Externa 1
CANCER CELL INTERNATIONAL 1475-2867 Externa 1
ONCOLOGY LETTERS 1792-1074 Externa 10
SUPPORTIVE CARE IN CANCER 0941-4355 Externa 6
ONCOLOGY REPORTS 1021-335X Externa 2
JOURNAL OF THORACIC ONCOLOGY 1556-0864 Externa 7
PATIENT-RELATED OUTCOME MEASURES 1179-271X Externa 1
DRUG DISCOVERY TODAY 1359-6446 Externa 1
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY 1756-283X Externa 1
INVESTIGATIONAL NEW DRUGS 0167-6997 Externa 2
JOURNAL OF IMMUNOTHERAPY 1524-9557 Externa 1
ACTA NEUROPATHOLOGICA 0001-6322 Externa 1
JOURNAL OF TRANSLATIONAL MEDICINE 1479-5876 Externa 6
ANNALS OF GASTROENTEROLOGICAL SURGERY 2475-0328 Externa 1
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY 1742-5255 Externa 1
ANNALS OF THE RHEUMATIC DISEASES 0003-4967 Externa 1
BMC PALLIATIVE CARE 1472-684X Externa 1
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY 1051-0443 Externa 1
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY 0174-1551 Externa 3
ONCOLOGY 0030-2414 Externa 2
RESPIRATORY RESEARCH 1465-993X Externa 1
ONKOLOGE 0947-8965 Externa 4
INTERNATIONAL IMMUNOPHARMACOLOGY 1567-5769 Externa 1
SEMINARS IN ONCOLOGY NURSING 0749-2081 Externa 1
CURRENT OPINION IN ONCOLOGY 1040-8746 Externa 4
WORLD JOURNAL OF SURGICAL ONCOLOGY 1477-7819 Externa 4
EXPERT OPINION ON INVESTIGATIONAL DRUGS 1354-3784 Externa 1
CLINICAL LUNG CANCER 1525-7304 Externa 2
AIMS GENETICS 2377-1143 Externa 1
CLINICAL EPIGENETICS 1868-7075 Externa 1
CRITICAL REVIEWS IN IMMUNOLOGY 1040-8401 Externa 1
PHARMACOGENOMICS & PERSONALIZED MEDICINE 1178-7066 Externa 1
CELL DEATH AND DIFFERENTIATION 1350-9047 Externa 1
BIOMARKERS IN MEDICINE 1752-0363 Externa 1
PATIENT EDUCATION AND COUNSELING 0738-3991 Externa 1
INTEGRATIVE CANCER THERAPIES 1534-7354 Externa 2
JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE 2383-7837 Externa 2
CYTOPATHOLOGY 0956-5507 Externa 1
CANCER MEDICINE 2045-7634 Externa 13
CANCER RADIOTHERAPIE 1278-3218 Externa 1
WORLD JOURNAL OF CLINICAL ONCOLOGY 2218-4333 Externa 1
SURGICAL CASE REPORTS 2198-7793 Externa 4
INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS 1386-5056 Externa 1
CLINICAL & EXPERIMENTAL METASTASIS 0262-0898 Externa 1
MOLECULAR BASIS OF NEUROPSYCHIATRIC DISORDERS: FROM BENCH TO BEDSIDE 1877-1173 Externa 1
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 2291-2789 Externa 1
ORVOSI HETILAP 0030-6002 Externa 1
ANNALS OF HEMATOLOGY 0939-5555 Externa 1
BMC SURGERY 1471-2482 Externa 1
PATHOLOGE 0172-8113 Externa 1
RADIATION ONCOLOGY 1748-717X Externa 1
JOURNAL OF GYNECOLOGIC ONCOLOGY 2005-0380 Externa 1
EUROPEAN JOURNAL OF RADIOLOGY 0720-048X Externa 1
TRADITIONAL MEDICINE RESEARCH 2413-3973 Externa 1
EUROPEAN UROLOGY ONCOLOGY 2588-9311 Externa 1
ANNALS ACADEMY OF MEDICINE SINGAPORE 0304-4602 Externa 1
PSYCHOLOGY HEALTH & MEDICINE 1354-8506 Externa 1
JOURNAL OF INTENSIVE CARE MEDICINE 0885-0666 Externa 1
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT 0885-3924 Externa 1
MEDECINE INTENSIVE REANIMATION 2496-6142 Externa 1
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 1743-7555 Externa 1
CANCER RESEARCH AND TREATMENT 1598-2998 Externa 2
ONCOGENESIS 2157-9024 Externa 1
THERAPEUTICS AND CLINICAL RISK MANAGEMENT 1178-203X Externa 1
PERSONALIZED MEDICINE 1741-0541 Externa 2
CLINICAL DRUG INVESTIGATION 1173-2563 Externa 2
ONCOLOGY IN CLINICAL PRACTICE 2450-1654 Externa 1
NPJ PRECISION ONCOLOGY 2397-768X Externa 1
JAMA ONCOLOGY 2374-2437 Externa 9
JOURNAL OF ONCOLOGY 1687-8450 Externa 1
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY 1756-2848 Externa 2
JOURNAL OF GASTROINTESTINAL ONCOLOGY 2078-6891 Externa 5
CELLULAR ONCOLOGY 2211-3428 Externa 2
GASTROENTEROLOGY RESEARCH AND PRACTICE 1687-6121 Externa 1
ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY 1220-0522 Externa 2
MOLECULAR THERAPY 1525-0016 Externa 1
FUTURE SCIENCE OA 2056-5623 Externa 1
PROCEEDINGS OF THE 4TH CONGRESS OF THE ROMANIAN SOCIETY FOR MINIMAL INVASIVE SURGERY IN GINECOLOGY / ANNUAL DAYS OF THE NATIONAL INSTITUTE FOR MOTHER AND CHILD HEALTH ALESSANDRESCU-RUSESCU 978-88-85813-48-9 Externa 1
JOURNAL OF NEURO-ONCOLOGY 0167-594X Externa 1
CANCER SCIENCE 1347-9032 Externa 4
MOLECULAR CANCER THERAPEUTICS 1535-7163 Externa 2
REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY 1507-1367 Externa 1
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH 2042-6305 Externa 1
KOREAN JOURNAL OF INTERNAL MEDICINE 1226-3303 Externa 1
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS 1084-9785 Externa 2
CAHIERS DE NUTRITION ET DE DIETETIQUE 0007-9960 Externa 1
CURRENT TREATMENT OPTIONS IN ONCOLOGY 1527-2729 Externa 3
ARCHIVES OF IRANIAN MEDICINE 1029-2977 Externa 1
ACTA MEDICA PORTUGUESA 1646-0758 Externa 2
CHINESE JOURNAL OF CANCER RESEARCH 1000-9604 Externa 1
CANCER EPIDEMIOLOGY 1877-7821 Externa 1
TRIALS 1745-6215 Externa 1
JOURNAL OF MEDICAL SYSTEMS 0148-5598 Externa 1
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES 1449-1907 Externa 1
CANCER IMMUNOLOGY RESEARCH 2326-6066 Externa 1
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY 1015-8987 Externa 1
EUROPEAN SURGERY-ACTA CHIRURGICA AUSTRIACA 1682-8631 Externa 1
MINERVA MEDICA 0026-4806 Externa 1
CURRENT OPINION IN UROLOGY 0963-0643 Externa 8
CURRENT COLORECTAL CANCER REPORTS 1556-3790 Externa 2
COLORECTAL DISEASE 1462-8910 Externa 9
GASTROENTEROLOGY REPORT 2052-0034 Externa 1
EUROPEAN JOURNAL OF ONCOLOGY NURSING 1462-3889 Externa 1
CLINICAL AND TRANSLATIONAL MEDICINE 2001-1326 Externa 1
BRACHYTHERAPY 1538-4721 Externa 1
STRAHLENTHERAPIE UND ONKOLOGIE 0179-7158 Externa 3
BMC MEDICAL GENOMICS 1755-8794 Externa 1
REVISTA BRASILEIRA DE GINECOLOGIA E OBSTETRICIA 0100-7203 Externa 1
CANCER CHEMOTHERAPY AND PHARMACOLOGY 0344-5704 Externa 6
CASE REPORTS IN ONCOLOGY 1662-6575 Externa 1
INTERNATIONAL JOURNAL OF QUALITATIVE STUDIES ON HEALTH AND WELL-BEING 1748-2623 Externa 1
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL 1911-6470 Externa 2
EUROPEAN JOURNAL OF CANCER CARE 0961-5423 Externa 1
RESPIRATORY CARE 0020-1324 Externa 1
JOURNAL OF BUON 1107-0625 Externa 2
HEAD & NECK PATHOLOGY 1936-055X Externa 1
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY 1948-5204 Externa 6
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM 1085-9489 Externa 1
MENOPAUSE REVIEW-PRZEGLAD MENOPAUZALNY 1643-8876 Externa 1
BJS OPEN 2474-9842 Externa 1
ONCOLOGY-NEW YORK 0890-9091 Externa 1
NEOPLASMA 0028-2685 Externa 1
INSIGHTS INTO IMAGING 1869-4101 Externa 1
PRECISION MEDICINE IN CANCER THERAPY 0927-3042 Externa 2
ANNALS OF GASTROENTEROLOGY 1108-7471 Externa 4
REANIMATION 1624-0693 Externa 1
CLINICAL COLORECTAL CANCER 1533-0028 Externa 13
SITC'S GUIDE TO MANAGING IMMUNOTHERAPY TOXICITY 978-0-8261-7214-3 Externa 1
NATURE REVIEWS DRUG DISCOVERY 1474-1776 Externa 1
CASE REPORTS IN ONCOLOGICAL MEDICINE 2090-6706 Externa 1
MOLECULAR AND CLINICAL ONCOLOGY 2049-9450 Externa 4
ANTI-CANCER DRUGS 0959-4973 Externa 1
CHIRURGIA 1221-9118 Externa 1
JOURNAL OF ONCOLOGY PHARMACY PRACTICE 1078-1552 Externa 5
PHARMACOGENOMICS 1462-2416 Externa 1
CLINICS IN COLON AND RECTAL SURGERY 1531-0043 Externa 1
CLINICAL GENITOURINARY CANCER 1558-7673 Externa 1
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS 1078-1439 Externa 1
OCHSNER JOURNAL 1524-5012 Externa 1
CANCER BIOMARKERS 1574-0153 Externa 3
TRANSLATIONAL ONCOLOGY 1936-5233 Externa 1
PHARMACEUTICAL RESEARCH 0724-8741 Externa 1
APPLIED HEALTH ECONOMICS AND HEALTH POLICY 1175-5652 Externa 1
JOURNAL OF RADIATION RESEARCH 0449-3060 Externa 1
JOURNAL OF DRUG ASSESSMENT 1369-9474 Externa 1
VOJNOSANITETSKI PREGLED 0042-8450 Externa 1
INTENSIVE CARE FOR EMERGENCY SURGEONS 2520-8284 Externa 2
IRANIAN JOURNAL OF RADIOLOGY 1735-1065 Externa 1
JOURNAL OF WOMENS HEALTH 1540-9996 Externa 1
MEDICAL ULTRASONOGRAPHY 1844-4172 Externa 1
ANNALS OF SURGICAL TREATMENT AND RESEARCH 2288-6575 Externa 1
INDIAN JOURNAL OF SURGICAL ONCOLOGY 0975-7651 Externa 2
JOURNAL OF SURGICAL CASE REPORTS 2042-8812 Externa 1
ONCOTARGET 1949-2553 Externa 22
CHINESE JOURNAL OF CANCER 1000-467X Externa 1
DANISH MEDICAL JOURNAL 2245-1919 Externa 1
COLORECTAL CANCER 1758-194X Externa 1
CLINICAL EPIGENETICS 1868-7083 Externa 1
JOURNAL OF THE ANUS RECTUM AND COLON 2432-3853 Externa 3
JAMA SURGERY 2168-6254 Externa 1
INTERNATIONAL JOURNAL OF COMPUTATIONAL SCIENCE AND ENGINEERING 1742-7185 Externa 1
AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY 1939-6163 Externa 1
SEMINARS IN COLON AND RECTAL SURGERY 1043-1489 Externa 1
ONKOLOGIJA 1408-1741 Externa 1
ANNALS OF COLOPROCTOLOGY 2287-9714 Externa 2
ANNALS OF LAPAROSCOPIC AND ENDOSCOPIC SURGERY 2518-6973 Externa 1
MINERVA CHIRURGICA 0026-4733 Externa 2
CANCER NURSING 0162-220X Externa 1
ASIAN JOURNAL OF SURGERY 1015-9584 Externa 1
DIGESTIVE ENDOSCOPY 0915-5635 Externa 1
INFECTIOUS AGENTS AND CANCER 1750-9378 Externa 1
GIORNALE DI CHIRURGIA 0391-9005 Externa 1
ACTA RADIOLOGICA OPEN 2058-4601 Externa 1
JOURNAL OF RURAL HEALTH 0890-765X Externa 1
JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE 1110-0362 Externa 1
GACETA MEXICANA DE ONCOLOGIA 1665-9201 Externa 1
VISZERALMEDIZIN 1662-6664 Externa 1
2015 12TH INTERNATIONAL CONFERENCE ON FUZZY SYSTEMS AND KNOWLEDGE DISCOVERY (FSKD) 978-1-4673-7682-2 Externa 1
SUCCESSES AND LIMITATIONS OF TARGETED CANCER THERAPY 0079-6263 Externa 1
2015 8TH INTERNATIONAL CONFERENCE ON BIOMEDICAL ENGINEERING AND INFORMATICS (BMEI) 978-1-5090-0022-7 Externa 1
UICC MANUAL OF CLINICAL ONCOLOGY, 9TH EDITION 978-1-4443-3244-5 Externa 1
COLORECTAL CANCER - FROM PATHOGENESIS TO TREATMENT 978-953-51-2544-0 Externa 1
MOLECULAR THERAPY OF BREAST CANCER: CLASSICISM MEETS MODERNITY 978-1-60741-593-0 Externa 1
TUMORS OF THE CENTRAL NERVOUS SYSTEM: BRAIN TUMORS (PT 2) 978-94-007-1705-3 Externa 1
CANCER REPORTS 2573-8348 Externa 1
KIDNEY CANCER 2468-4562 Externa 4

Listado ordenado (según número de citas) de Revistas que citan a la revista consultada en este perfil.

: Las citas a esta revista provienen de documentos no incluidos en la base de datos de DATACIENCIA

Publicaciones



Título Año Citas
I Mpower133: Updated Overall Survival (Os) Analysis Of First Line (1 L) Atezolizumab (Atezo) Plus Carboplatin Plus Etoposide In Extensive Stage Sclc (Es Sclc) 2019 41
Health Related Quality Of Life (Hr Qo L) Impact Of Pembrolizumab (Pembro) Versus Best Supportive Care (Bsc) In Previously Systemically Treated Patients (Pts) With Advanced Hepatocellular Carcinoma (Hcc): Keynote 240 2019 2
Alpelisib (Alp) Plus Fulvestrant (Ful) For Patients With Hormone Receptor Positive (Hr+), Her2 Advanced Breast Cancer (Abc): Management And Time Course Of Key Adverse Events Of Special Interest (Aes Is) In Solar 1 2019 3
Efficacy And Safety Of Nivolumab In Combination With Docetaxel In Men With Metastatic Castration Resistant Prostate Cancer In Check Mate 9 Kd 2019 0
Pembrolizumab With Or Without Chemotherapy Vs Chemotherapy In Patients With Advanced G/Gej Cancer (Gc) Including Outcomes According To Microsatellite Instability High (Msi H) Status In Keynote 062 2019 16
Phase Iii Study Of Veliparib With Carboplatin And Paclitaxel In Her2 Negative Advanced/Metastatic G Brca Associated Breast Cancer 2019 31
I Mpower150: An Exploratory Analysis Of Efficacy Outcomes In Patients With Egfr Mutations 2019 5
Final Analysis Of The Phase Iii Keynote 042 Study: Pembrolizumab (Pembro) Versus Platinum Based Chemotherapy (Chemo) As First Line Therapy For Patients (Pts) With Pd L1 Positive Locally Advanced/Metastatic Nsclc 2019 11
Pembrolizumab With Or Without Chemotherapy Versus Chemotherapy For First Line Treatment Of Advanced Gastric Or Gastroesophageal Junction (G/Gej) Adenocarcinoma: The Phase 3 Keynote 062 Study 2019 1
Quality Of Life And Preoperative Chemotherapy In Gastric Cancer In Chile: Results From The Observational Study Of Perioperative Chemotherapy In Gastric Cancer (Preciso) 2019 2
Pembrolizumab (Pembro) Therapy Vs Best Supportive Care (Bsc) In Advanced Hepatocellular Carcinoma (Hcc): Keynote 240 2019 0
Use Of Archival Versus Newly Collected Tumor Samples For Assessing Pd L1 Expression And Overall Survival: An Updated Analysis Of Keynote 010 Trial 2019 71
Empower Lung 1: A Randomized, Open Label, Multi National, Phase Iii Trial Of Cemiplimab, A Human Pd 1 Monoclonal Antibody, Versus Chemotherapy In First Line Treatment Of Advanced Non Small Cell Lung Cancer (Nsclc) With Pd L1 >= 50% 2018 1
I Mpower131: Progression Free Survival (Pfs) And Overall Survival (Os) Analysis Of A Randomised Phase Iii Study Of Atezolizumab Plus Carboplatin Plus Paclitaxel Or Nab Paclitaxel Vs Carboplatin Plus Nab Paclitaxel In 1 L Advanced Squamous Nsclc 2018 1
Major Determinants Of Delayed Access To Innovative Medicines For Metastatic Melanoma: The Results Of Melanoma World Society And European Association Of Dermato Oncology Survey 2018 0
I Mpower150: Clinical Safety, Tolerability And Immune Related Adverse Events In A Phase Iii Study Of Atezolizumab (Atezo) Plus Chemotherapy (Chemo) +/ Bevacizumab (Bev) Vs Chemo + Bev In 1 L Nonsquamous Nsclc 2018 2
First Report Of Znf518 B Gene Expression As A Prognostic Factor In Colorectal Cancer Development: Role In Tissue Invasiveness 2018 1
I Mpower150: An Exploratory Analysis Of Efficacy Outcomes In Patients With Egfr Mutations 2018 1
Phase Iii, Randomised Trial Of Avelumab Versus Physician's Choice Of Chemotherapy As Third Line Treatment Of Patients With Advanced Gastric Or Gastro Oesophageal Junction Cancer: Primary Analysis Of Javelin Gastric 300 2018 318
Keynote 061: Phase 3 Study Of Pembrolizumab Vs Paclitaxel For Previously Treated Advanced Gastric Or Gastroesophageal Junction (G/Gej) Cancer 2018 5
Nivolumab Versus Docetaxel In Previously Treated Advanced Non Small Cell Lung Cancer (Check Mate 017 And Check Mate 057): 3 Year Update And Outcomes In Patients With Liver Metastases 2018 325
Keynote 033: Phase 3 Study Of Pembrolizumab Versus Docetaxel In Patients With Previously Treated Non Small Cell Lung Cancer (Nsclc) 2017 2
Primary Pfs And Safety Analyses Of A Randomized Phase Iii Study Of Carboplatin Plus Paclitaxel Plus / Bevacizumab, With Or Without Atezolizumab In 1 L Non Squamous Metastatic Nsclc (Impower150) 2017 8
Check Mate 214: Efficacy And Safety Of Nivolumab Plus Ipilimumab (N Plus I) V Sunitinib (S) For Treatment Naive Advanced Or Metastatic Renal Cell Carcinoma (M Rcc), Including Imdc Risk And Pd L1 Expression Subgroups 2017 51
Keynote 059 Update: Efficacy And Safety Of Pembrolizumab Alone Or In Combination With Chemotherapy In Patients With Advanced Gastric Or Gastroesophageal (G/Gej) Cancer 2017 36
Three Year Follow Up From Check Mate 017/057: Nivolumab Versus Docetaxel In Patients With Previously Treated Advanced Non Small Cell Lung Cancer (Nsclc) 2017 5
Prediction Of Local And Metastatic Recurrence In Solitary Fibrous Tumor: Construction Of A Risk Calculator In A Multicenter Cohort From The French Sarcoma Group (Fsg) Database 2017 65
Keynote 059 Cohort 3: Safety And Efficacy Of Pembrolizumab Monotherapy For First Line Treatment Of Patients (Pts) With Pd L1 Positive Advanced Gastric/Gastroesophageal (G/Gej) Cancer 2017 5
Prognosis Factors Of Survival Of Gallbladder Cancer (Gc) In Chile. A Retrospective Analysis Of Patients Assisted In Hospital Clinico Universidad De Chile 2017 0
Global, Phase 3 Study Of First Line Durvalumab (Medi4736) + Tremelimumab Vs Standard Of Care Platinum Based Chemotherapy In Advanced/Metastatic Nsclc: Neptune 2016 1
Pembrolizumab (Pembro) Vs Docetaxel (Doce) For Previously Treated, Pd L1 Expressing Nsclc: Updated Outcomes Of Keynote 010 2016 3
Heritage, A Phase Iii Safety And Efficacy Trial Of The Proposed Trastuzumab Biosimilar, Myl 1401 O Vs Trastuzumab 2016 2
First Line Triplet Or Doublet Chemotherapy For Advanced Gastric Cancer: Analysis Of 970 Patients From A Community Practice Registry 2016 1
Planning And Reporting Of Quality Of Life Outcomes In Cancer Trials (Vol 26, Pg 1966, 2015) 2016 5
Keynote 010: Phase 2/3 Study Of Pembrolizumab (Mk 3475) Vs Docetaxel For Pd L1 Positive Nsclc After Platinum Based Therapy 2015 2
Phase 3, Randomised, Open Label Study Of Durvalumab (Medi4736) In Combination With Tremelimumab Versus Platinum Based Chemotherapy In First Line Treatment Of Patients With Advanced Or Metastatic Nsclc: Neptune 2015 0
The Outcomes Of The Fecal Occult Blood Testing For Colorectal Cancer In One Local Hospital In Chile: Results Of A First Two Year International Collaborative Study Between Chile And Japan 2015 0
Intensive Care In Patients With Lung Cancer: A Multinational Study 2014 57
Evaluation Of Docetaxel, Cisplatin And Capecitabine (Dcx) As Perioperative Chemotherapy For Resectable Gastric And Esophago Gastric Cancer 2014 0
Overall Survival Benefit For Sequential Doxorubicin Docetaxel Compared With Concurrent Doxorubicin And Docetaxel In Node Positive Breast Cancer 8 Year Results Of The Breast International Group 02 98 Phase Iii Trial 2013 18
Esmo Consensus Guidelines For Management Of Patients With Colon And Rectal Cancer. A Personalized Approach To Clinical Decision Making 2012 1000
Screening And Triage Test For Early Detection Of Gastric Cancer (Stead Gc) 2012 0
Determination Of The Her2 Expression In Chilean Patients With Gastric Cancer 2012 0
The Unforeseen Impact Of Meeting Abstracts On Cancer Research 2011 3
Non Hodgkin Lymphoma (Nhl) In Chile. A Review Of 207 Consecutive Adult Nhl Cases By A Panel Of Five Expert Hematopathologists 2011 0
A Phase Ii Study To Investigate The Prevalence Of Infectious Agents In Ocular Adnexae Marginal Zone Lymphoma (Oamzl) And The Efficacy Of Antibiotic Therapy (Ielsg#27 Trial) 2011 1
The Number Of Lymph Nodes Examined Is A Prognostic Factor For Survival Of Patients With Colon Cancer Stage Ii 2011 0
Safety And Efficacy Results From A Phase 1/2 Study Of The Anti Igf Ir Antibody Figitumumab In Patients With Refractory Ewing's And Other Sarcomas 2010 2
The Activity Of Mrp1 Membrane Transporter Confers Resistance To Anticancer Drugs In Glioblastoma Multiforme Cells 2010 0
Palliative Chemotherapy With Docetaxel Cisplatin For Advanced Gastric Cancer In A Non Selected Patient Population In Chile 2009 0
Breast Cancer In Latin America: Expert Perceptions Compared With Medical Care Standards (Mcs) 2009 0
Is Risk Of Central Nervous System (Cns) Relapse Related To Adjuvant Taxane Treatment In Node Positive Breast Cancer? Results Of The Cns Substudy In The Intergroup Phase Iii Big 02 98 Trial 2008 16
Nivolumab (Nivo) Plus Platinum Doublet Chemotherapy (Chemo) Vs Chemo As First Line (1 L) Treatment (Tx) For Advanced Non Small Cell Lung Cancer (A Nsclc): Check Mate 227 Part 2 Final Analysis 2019 3
Nivolumab Plus Low Dose Ipilimumab As First Line Treatment Of Advanced Nsclc: Overall Survival Analysis Of Checkmate 817 2019 13
Pembrolizumab Plus Chemotherapy For Advanced G/Gej Adenocarcinoma (Gc): The Phase Iii Keynote 062 Study 2019 0
Znf518 B As A Transcriptional Factor Involved In Colorectal Cancer Progression Through The Epithelial To Mesenchymal Transition 2019 0
Pembrolizumab With Or Without Chemotherapy Versus Chemotherapy For First Line Treatment Of Advanced Gastric Or Gastroesophageal Junction (G/Gej) Adenocarcinoma: The Phase 3 Keynote 062 Study 2019 0
Pembrolizumab (Pembro) Therapy Vs Best Supportive Care (Bsc) In Advanced Hepatocellular Carcinoma (Hcc): Keynote 240 2019 0
Quality Of Life And Preoperative Chemotherapy In Gastric Cancer In Chile: Results From The Observational Study Of Perioperative Chemotherapy In Gastric Cancer (Preciso) 2019 0
Prognosis Factors Of Survival Of Gallbladder Cancer (Gc) In Chile. A Retrospective Analysis Of Patients Assisted In Hospital Clínico Universidad De Chile 2017 0
I Mpower131: Progression Free Survival (Pfs) And Overall Survival (Os) Analysis Of A Randomised Phase Iii Study Of Atezolizumab + Carboplatin + Paclitaxel Or Nab Paclitaxel Vs Carboplatin + Nab Paclitaxel In 1 L Advanced Squamous Nsclc 2018 0
I Mpower150: Clinical Safety, Tolerability And Immune Related Adverse Events In A Phase Iii Study Of Atezolizumab (Atezo) + Chemotherapy (Chemo) ± Bevacizumab (Bev) Vs Chemo + Bev In 1 L Nonsquamous Nsclc 2018 0
Planning And Reporting Of Quality Of Life Outcomes In Cancer Trials 2015 0
Keynote 061: Response To Subsequent Therapy Following Second Line Pembrolizumab Or Paclitaxel In Patients With Advanced Gastric Or Gastroesophageal Junction Adenocarcinoma 2020 6
Time Course And Management Of Key Adverse Events During The Randomized Phase Iii Solar 1 Study Of Pi3 K Inhibitor Alpelisib Plus Fulvestrant In Patients With Hr Positive Advanced Breast Cancer 2020 58
Patient (Pt) Preference And Satisfaction With The Subcutaneous Fixed Dose Combination Of Pertuzumab (P) And Trastuzumab (H) In Pts With Her2 Positive Early Breast Cancer (Her2+E Bc): Interim Analysis Of The Open Label, Randomised Cross Over P Hrance S Ca Study 2020 0
Nivolumab (Nivo) Plus Chemotherapy (Chemo) Versus Chemo As First Line (1 L) Treatment For Advanced Gastric Cancer/Gastroesophageal Junction Cancer (Gc/Gejc)/Esophageal Adenocarcinoma (Eac): First Results Of The Check Mate 649 Study 2020 155
Leap 005: Phase Ii Study Of Lenvatinib (Len) Plus Pembrolizumab (Pembro) In Patients (Pts) With Previously Treated Advanced Solid Tumours 2020 42
Single Agent Anti Pd 1 Balstilimab Or In Combination With Anti Ctla 4 Zalifrelimab For Recurrent/Metastatic (R/M) Cervical Cancer (Cc): Preliminary Results Of Two Independent Phase Ii Trials 2020 28
Nivolumab Plus Cabozantinib Vs Sunitinib In First Line Treatment For Advanced Renal Cell Carcinoma: First Results From The Randomized Phase Iii Check Mate 9 Er Trial 2020 97
Health Related Quality Of Life (Hr Qo L) In Keynote 604: Pembrolizumab (Pembro) Or Placebo Added To Etoposide And Platinum (Ep) As First Line Therapy For Es Sclc 2020 4
Albumin As A Simple Criterion To Reduce Early Mortality (Em) In Gastric Cancer (Gc) Trials 2020 1
Association Of Tmb Using The Foundation Medicine Companion Diagnostic (F1 C Dx) With Efficacy Of First Line Pembrolizumab (Pembro) Or Pembro Plus Chemotherapy (Pembro Plus Chemo) Versus Chemo In Patients With Gastric Cancer (Gc) From Keynote 062 2020 11
I Mpower150: Updated Efficacy Analysis In Patients With Egfr Mutations 2020 11
I Mscin001: Phase Ib Dose Finding Study Of Subcutaneous Atezolizumab In Patients With Locally Advanced Or Metastatic Non Small Cell Lung Cancer (Nsclc) 2020 0
Randomized, Open Label Phase Iii Study Of Pembrolizumab (Pembro) Vs Docetaxel (Doce) In Patients (Pts) With Previously Treated Nsclc With Pd L1 Tumour Proportion Score (Tps) ≥1%: Keynote 033 2020 4
Outcome And Toxicity In Older Patients With Locoregionallyadvanced Head And Neck Cancer: Relevance Of An Oncogeriatric Approach 2020 0
Comparing Frailty Screening Tools For Older Head And Neck Cancer Patients 2020 1
Impact Of Geriatric Assessment On The Management Of Older Head And Neck Cancer Patients 2020 1
A Phase Ii Study Of Patients With Advanced Or Metastatic Renal Cell Carcinoma (M Rcc) Receiving Pazopanib After Previous Checkpoint Inhibitor Treatment 2020 4
Patient (Pt) Preference For The Pertuzumab Trastuzumab Fixed Dose Combination For Subcutaneous Use (Ph Fdc Sc) In Her2 Positive Early Breast Cancer (Ebc): Primary Analysis Of The Open Label, Randomised Crossover P Hrance S Ca Study 2020 8
Nivolumab Plus Ipilimumab (N Plus I) Vs Sunitinib (S) For First Line Treatment Of Advanced Renal Cell Carcinoma (A Rcc) In Check Mate 214: 4 Year Follow Up And Subgroup Analysis Of Patients (Pts) Without Nephrectomy 2020 18
Survival Of Responders To Nivolumab (Nivo) Plus Ipilimumab (Ipi) As First Line Treatment For Advanced Nsclc In Check Mate 227, Part 1 2020 2
Final Efficacy Results From I Mpower132: First Line Atezolizumab Plus Chemotherapy In Patients With Stage Iv Non Squamous Nsclc 2020 6
Phase Iii Keynote 355 Study Of Pembrolizumab (Pembro) Vs Placebo (Pbo) Plus Chemotherapy (Chemo) For Previously Untreated Locally Recurrent Inoperable Or Metastatic Triple Negative Breast Cancer (Tnbc): Results For Patients (Pts) Enrolled In Asia 2020 1
Molecular Determinants Of Clinical Outcomes With Pembrolizumab Versus Paclitaxel In A Randomized, Open Label, Phase Iii Trial In Patients With Gastroesophageal Adenocarcinoma 2021 28
Initial Data From The Phase 3 Keynote 811 Study Of Trastuzumab And Chemotherapy With Or Without Pembrolizumab For Her2 Positive Metastatic Gastric Or Gastroesophageal Junction (G/Gej) Cancer 2021 3
Pt Hr P And Sparc Expressions In Human Colorectal Cancer: An In Silico Analysis 2021 0
A Phase 2 Multicohort Study (Leap 005) Of Lenvatinib Plus Pembrolizumab In Patients With Previously Treated Selected Solid Tumors: Pancreatic Cancer Cohort 2021 1
Molecular Profiling Of Kit And Pdgfra In Chilean Gist Patients: A Latin American Perspective 2021 0
Continuous Versus Intermittent Extended Adjuvant Letrozole For Breast Cancer: Final Results Of Randomized Phase Iii Sole (Study Of Letrozole Extension) And Sole Estrogen Substudy 2021 11
An Unwelcome Guest: P. Gingivalis Intratumoral Infection And Immune Evasion In Gastric Cancer 2021 0
Nivolumab (Nivo) Plus Ipilimumab (Ipi) As First Line (1 L) Treatment (Tx) For Patients (Pts) With Advanced Nsclc (A Nsclc) And Baseline (Bl) Brain Metastases (Mets): Intracranial And Systemic Outcomes From Check Mate 227 Part 1 2021 6
Pembrolizumab Plus Ipilimumab Or Placebo In Previously Untreated Metastatic Nsclc With Pd L1 Tumor Proportion Score ≥50%: Keynote 598 3 Year Follow Up 2022 2
Open Label, Phase Ii Study Of Tusamitamab Ravtansine (Sar408701) In Combination With Pembrolizumab And With Pembrolizumab Plus Platinum Based Chemotherapy Plus / Pemetrexed In Patients With Ceacam5 Positive Nonsquamous Nsclc (Carmen Lc05) 2022 0
Nivolumab (Nivo) Plus Chemotherapy (Chemo) Or Ipilimumab (Ipi) Vs Chemo As First Line (1 L) Treatment For Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophageal Adenocarcinoma (Gc/Gejc/Eac): Check Mate 649 Study 2021 18
Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy For Persistent, Recurrent, Or Metastatic Cervical Cancer: Randomized, Double Blind, Phase Iii Keynote 826 Study 2021 1
Keynote 355: Final Results From A Randomized, Double Blind Phase Iii Study Of First Line Pembrolizumab Plus Chemotherapy Vs Placebo Plus Chemotherapy For Metastatic Tnbc 2021 42
Evaluation Of Gonyautoxins (Gtx) On Objective And Subjective Symptoms Of Chemotherapy Induced Peripheral Neuropathy (Cipn) 2021 0
Survival Impact Of Concurrent Chemoradiotherapy (Crt) With Weekly Cisplatin Doses In Patients With Unresectable Stage Iii Non Small Cell Lung Cancer (Nsclc) In A Clinical Referral Center In Chile 2021 0
First Line Nivolumab Plus Cabozantinib Vs Sunitinib In Patients (Pts) With Advanced Renal Cell Carcinoma (A Rcc) In Subgroups Based On Prior Nephrectomy In The Check Mate 9 Er Trial 2021 0
Relatlimab (Rela) Plus Nivolumab (Nivo) Vs. Nivo In Previously Untreated Metastatic Or Unresectable Melanoma: Additional Efficacy In Relativity 047 2021 1
Conditional Survival And 5 Year Follow Up In Check Mate 214: First Line Nivolumab Plus Ipilimumab (N Plus I) Versus Sunitinib (S) In Advanced Renal Cell Carcinoma (A Rcc) 2021 24
Check Mate 9 Kd Cohort A2 Final Analysis: Nivolumab (Nivo) Plus Rucaparib For Chemotherapy (Ct) Naive Metastatic Castration Resistant Prostate Cancer (M Crpc) 2021 9
Pembrolizumab (Pembro) Vs Placebo As Adjuvant Therapy For Patients (Pts) With Renal Cell Carcinoma (Rcc): Patient Reported Outcomes (Pro) In Keynote 564 2021 3
Genomic Characterisation Of Hormone Receptor Positive Breast Cancer Arising In Very Young Women 2023 2
Alta 3: A Randomized Trial Of Brigatinib (Brg) Vs Alectinib (Alc) In Crizotinib (Crz) Refractory Advanced Alk Plus Nsclc 2022 0
Phase Iii Study Of Cabozantinib (C) In Combination With Nivolumab (N) And Ipilimumab (I) In Previously Untreated Advanced Renal Cell Carcinoma (A Rcc) Of Imdc Intermediate Or Poor Risk (Cosmic 313) 2022 9
Metastasis Resident Bacteria In Advanced Hormone Receptor Positive Breast Cancer Are Related To Primary Tumor Microbiota And Show Distinct Composition 2022 0
Pembrolizumab Plus Olaparib Vs Abiraterone (Abi) Or Enzalutamide (Enza) For Patients (Pts) With Previously Treated Metastatic Castration Resistant Prostate Cancer (M Crpc): Randomized Open Label Phase Iii Keylynk 010 Study 2022 3
Phase Ii Trial Evaluating Effect Of Gonyautoxins (Gtx), A Paralytic Shellfish Poisoning (Psp) On Objective And Subjective Symptoms Of Chemotherapy Induced Peripheral Neuropathy (Cipn) 2022 0
First Line Lenvatinib (Len) Plus Pembrolizumab (Pembro) Plus Chemotherapy (Chemo) Vs Chemo In Advanced/Metastatic Gastroesophageal Adenocarcinoma: Leap 015 Safety Run In 2022 0
1 Year Follow Up Of A Phase Iii Study To Compare Efficacy And Safety Of A Bevacizumab Biosimilar, Ct P16, And Reference Bevacizumab As First Line Treatment For Metastatic Or Recurrent Non Squamous Non Small Cell Lung Cancer 2022 0
Nivolumab (Nivo) Plus Relatlimab (Rela) Vs Nivo In Previously Untreated Metastatic Or Unresectable Melanoma: Additional Response Outcomes From Relativity 047 2022 0
Pivot Io 001: First Disclosure Of Efficacy And Safety Of Bempegaldesleukin (Bempeg) Plus Nivolumab (Nivo) Vs Nivo Monotherapy In Advanced Melanoma (Mel) 2022 6
Pembrolizumab (Pembro) Vs Placebo (Pbo) As Second Line Treatment For Sorafenib Treated Advanced Hepatocellular Carcinoma (A Hcc): 4.5 Year Follow Up From Keynote 240 2022 1
Gut Microbiome Characterization And Correlation With Colonoscopy Findings In Oncological And Non Oncological Patients From A Chilean Cancer Center 2022 0
Oxidized Ldl Promotes Colorectal Cancer Progression And Growth Of Human Colonoides 2022 0
Health Related Quality Of Life (Hr Qo L) With Pembrolizumab (Pembro) Plus Chemotherapy (Chemo) Vs Placebo (Pbo) + Chemo As 1 L Treatment For Advanced Triple Negative Breast Cancer (Tnbc): Results From Keynote 355 2022 0
Pembrolizumab (Pembro) Plus Chemotherapy (Chemo) As First Line Therapy For Advanced Her2 Negative Gastric Or Gastroesophageal Junction (G/Gej) Cancer: Phase Iii Keynote 859 Study 2023 11
I Mscin001 Part 2: A Randomised Phase Iii, Open Label, Multicentre Study Examining The Pharmacokinetics, Efficacy, Immunogenicity, And Safety Of Atezolizumab Subcutaneous Versus Intravenous Administration In Previously Treated Locally Advanced Or Metastatic Non Small Cell Lung Cancer And Pharmacokinetics Comparison With Other Approved Indications 2023 0
Additional Data From The Keynote 859 Study Of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy For Advanced Her2 Negative Gastric Or Gastroesophageal Junction (G/Gej) Cancer 2023 0
Spatially Resolved Detection Of Premalignant Lesions And Immune Infiltration In Gastric Endoscopic Biopsies Using Multiplexed Immunofluorescence And Correlation With Olga/Olgim Assessment 2023 0
Flaura2: Safety And Cns Outcomes Of First Line (1 L) Osimertinib (Osi) ± Chemotherapy (C Tx) In Egf Rm Advanced Nsclc 2023 0
Safety Run In Results From Leap 014: First Line Lenvatinib (Len) Plus Pembrolizumab (Pembro) And Chemotherapy (Chemo) For Metastatic Esophageal Squamous Cell Carcinoma (Escc) 2023 0
Pathological Complete Response (P Cr) To Durvalumab Plus 5 Fluorouracil, Leucovorin, Oxaliplatin And Docetaxel (Flot) In Resectable Gastric And Gastroesophageal Junction Cancer (Gc/Gejc): Interim Results Of The Global, Phase Iii Matterhorn Study 2023 0
The Phase Iii, Randomized, Double Blind, Placebo Controlled Keynote 811 Study Of Pembrolizumab Plus Trastuzumab And Chemotherapy For Her2+Metastatic Gastric Or Gastroesophageal Junction (M G/Gej) Adenocarcinoma 2023 0
Progression Of Disease Within 5 Months Of Adult T Cell Leukemia Lymphoma (Atl5) As A Clinical Endpoint For High Risk Mortality Outcomes 2023 0
Belzutifan Versus Everolimus In Participants (Pts) With Previously Treated Advanced Clear Cell Renal Cell Carcinoma (Cc Rcc): Randomized Open Label Phase Iii Litespark 005 Study 2023 5
Nivolumab Plus Gemcitabine Cisplatin Versus Gemcitabinecisplatin Alone For Previously Untreated Unresectable Or Metastatic Urothelial Carcinoma: Results From The Phase Iii Check Mate 901 Trial 2023 3
Pembrolizumab Plus Chemotherapy Vs Chemotherapy As Neoadjuvant And Adjuvant Therapy In Locally Advanced Gastric And Gastroesophageal Junction Cancer: The Phase Iii Keynote 585 Study 2023 4
Pathological Complete Response (P Cr) To Durvalumab Plus 5 Fluorouracil, Leucovorin, Oxaliplatin And Docetaxel (Flot) In Resectable Gastric And Gastroesophageal Junction Cancer (Gc/Gejc): Interim Results Of The Global, Phase Iii Matterhorn Study 2023 6
Flaura2: Safety And Cns Outcomes Of First Line (1 L) Osimertinib (Osi) ± Chemotherapy (C Tx) In Egf Rm Advanced Nsclc 2023 0
A Randomized, Double Blind Trial Of Nivolumab (Nivo) Vs Placebo (Pbo) With Neoadjuvant Chemotherapy (Nact) Followed By Adjuvant Endocrine Therapy (Et) ± Nivo In Patients (Pts) With High Risk, Er+Her2 L Primary Breast Cancer (Bc) 2023 2
Pembrolizumab Plus Chemoradiotherapy For High Risk Locally Advanced Cervical Cancer: A Randomized, Doubleblind, Phase Iii Engot Cx11/Gog 3047/Keynote A18 Study 2023 5
Pembrolizumab (Pembro) Plus Enzalutamide (Enza) For Patients (Pts) With Metastatic Castration Resistant Prostate Cancer (M Crpc): Randomized Double Blind Phase Iii Keynote 641 Study 2023 1
Real World Gastric Cancer (Gc) In Latin America (Latam) And Europe (Eu) 2023 0
Clinical Multi Omics Analysis Of Gastric Cancer (Gc) In Europe (Eu) And Latin America (Lat Am): The Lega Cy Project 2023 0
First Line Lenvatinib (Len) Plus Pembrolizumab (Pembro) And Chemotherapy (Chemo) For Metastatic Esophageal Squamous Cell Carcinoma (M Escc): Safety Run In Results From The Phase Iii Leap 014 Study 2023 0
Health Related Quality Of Life (Hrqol) Analysis From Keynote 859: First Line (1 L) Pembrolizumab (Pembro) Plus Chemotherapy (Chemo) For Advanced Her2 Negative Gastric Or Gastroesophageal Junction (G/Gej) Adenocarcinoma 2023 0
Pembrolizumab Plus Trastuzumab And Chemotherapy For Her2+Metastatic Gastric Or Gastroesophageal Junction (M G/ Gej) Adenocarcinoma: Survival Results From The Phase Iii, Randomized, Double Blind, Placebo Controlled Keynote 811 Study 2023 0
I Mscin001 Part 2 Updated Results: Efficacy, Safety, Immunogenicity And Patient Reported Outcomes (Pr Os) From The Randomised Phase Iii Study Of Atezolizumab (Atezo) Subcutaneous (Sc) Vs Intravenous (Iv) In Patients With Locally Advanced Or Metastatic Non Small Cell Lung Cancer (Nsclc) 2023 0
Prevalence Of Egfr Mutations (Egf Rm) In Patients (Pts) With Resected Stage I Iii Nsclc: Results From Early Egfr Latam 2023 0
Safety And Preliminary Efficacy Of The Kras G12 C Inhibitor Mk 1084 In Solid Tumors And In Combination With Pembrolizumab In Nsclc 2023 1
Corrigendum To ‘I Mscin001 Part 2: A Randomised Phase Iii, Open Label, Multicentre Study Examining The Pharmacokinetics, Efficacy, Immunogenicity, And Safety Of Atezolizumab Subcutaneous Versus Intravenous Administration In Previously Treated Locally Advanced Or Metastatic Non Small Cell Lung Cancer And Pharmacokinetics Comparison With Other Approved Indications’: [Annals Of Oncology 34 (2023) P693 702, (S0923753423006944), (10.1016/J.Annonc.2023.05.009)] 2024 0

Listado de publicaciones y sus citas para la revista seleccionada.


Descargar Descarga los datos de esta página (formato JSON).
Descargar Descarga los datos de esta página como un archivo Excel.